Corvus Pharmaceuticals (CRVS) Capital Expenditures Growth (5y) (2020 - 2026)

Corvus Pharmaceuticals (CRVS) Capital Expenditures Growth (5y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Corvus Pharmaceuticals 1.17 Bn 934.14 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -32.80%
Dec 31, 2025 -45.26%
Sep 30, 2025 76.14%
Dec 31, 2024 97.13%
Sep 30, 2024 -137.46%
Mar 31, 2024 -81.60%
Mar 31, 2023 -29.41%
Dec 31, 2022 27.26%
Sep 30, 2022 16.93%
Dec 31, 2021 16.85%
Sep 30, 2021 -16.52%
Jun 30, 2021 -111.28%
Mar 31, 2021 2.05%
Dec 31, 2020 16.89%
Sep 30, 2020 -15.15%